D.E. Shaw & Co
MYGN icon

D.E. Shaw & Co’s Myriad Genetics MYGN Stock Holding History

D.E. Shaw & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,300
Closed -$251K – 3686
2017
Q4 		$251K Buy
+7,300
New +$246K ﹤0.01% 3329
2017
Q3 		– Sell
-32,400
Closed -$837K – 3548
2017
Q2 		$837K Hold
32,400
– – ﹤0.01% 2520
2017
Q1 		$622K Buy
+32,400
New +$574K ﹤0.01% 2615

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's MYGN Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Myriad Genetics (MYGN) stake by 0.12% in Q1 2026, selling an estimated $28.5K and leaving 4,499,724 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #1139.

D.E. Shaw & Co first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $179M in Q3 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • D.E. Shaw & Co held 4,499,724 shares of Myriad Genetics worth $20.2M as of Q1 2026.
  • D.E. Shaw & Co sold 5,469 Myriad Genetics shares in Q1 2026, an estimated $28.5K.
  • Myriad Genetics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1139 holding.
  • D.E. Shaw & Co first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's Myriad Genetics position peaked at $179M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.